IL99889A - תולדות 3-אוקסו אזאאנדרוסטן b71- קרבוקסאמיד, תהליכים להכנתן רוקחות המכילים אותן - Google Patents

תולדות 3-אוקסו אזאאנדרוסטן b71- קרבוקסאמיד, תהליכים להכנתן רוקחות המכילים אותן

Info

Publication number
IL99889A
IL99889A IL9988991A IL9988991A IL99889A IL 99889 A IL99889 A IL 99889A IL 9988991 A IL9988991 A IL 9988991A IL 9988991 A IL9988991 A IL 9988991A IL 99889 A IL99889 A IL 99889A
Authority
IL
Israel
Prior art keywords
groups
substituted
group
carbon
carbon atoms
Prior art date
Application number
IL9988991A
Other languages
English (en)
Other versions
IL99889A0 (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL99889A0 publication Critical patent/IL99889A0/xx
Publication of IL99889A publication Critical patent/IL99889A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9988991A 1990-10-29 1991-10-29 תולדות 3-אוקסו אזאאנדרוסטן b71- קרבוקסאמיד, תהליכים להכנתן רוקחות המכילים אותן IL99889A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29140190 1990-10-29

Publications (2)

Publication Number Publication Date
IL99889A0 IL99889A0 (en) 1992-08-18
IL99889A true IL99889A (he) 1995-06-29

Family

ID=17768420

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9988991A IL99889A (he) 1990-10-29 1991-10-29 תולדות 3-אוקסו אזאאנדרוסטן b71- קרבוקסאמיד, תהליכים להכנתן רוקחות המכילים אותן

Country Status (20)

Country Link
US (1) US5302621A (he)
EP (1) EP0484094B1 (he)
JP (1) JPH0819151B2 (he)
KR (1) KR0134570B1 (he)
CN (2) CN1053672C (he)
AT (1) ATE139783T1 (he)
AU (1) AU640279B2 (he)
CA (1) CA2054368C (he)
CZ (1) CZ279312B6 (he)
DE (1) DE69120500T2 (he)
DK (1) DK0484094T3 (he)
ES (1) ES2091299T3 (he)
GR (1) GR3020483T3 (he)
HK (2) HK1005456A1 (he)
HU (2) HU218667B (he)
IE (1) IE76452B1 (he)
IL (1) IL99889A (he)
PT (1) PT99371B (he)
RU (1) RU2070204C1 (he)
ZA (1) ZA918570B (he)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
ES2118222T3 (es) * 1991-12-20 1998-09-16 Glaxo Wellcome Inc Inhibidores de 5-alfa-testosterona reductasa.
ATE154937T1 (de) * 1992-04-20 1997-07-15 Sankyo Co Steroide zur behandlung von prostatisch- hypertrophe, ihre herstellung und verwendung
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク エンド カンパニー インコーポレーテッド 5α−レダクターゼ阻害剤としての3−オキソ−4−アザステロイドの新規17−エステル,アミド及びケトン誘導体
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
DE69329933T2 (de) * 1992-10-06 2001-07-19 Merck & Co., Inc. 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
WO1994022900A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
ATE178795T1 (de) * 1993-11-04 1999-04-15 Merck & Co Inc 7-substituierte-4-aza-steroid-derivate als 5- alpha-reductase-hemmer
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
IT1271325B (it) * 1994-12-23 1997-05-27 Poli Ind Chimica Spa Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
CN1072679C (zh) * 1995-07-30 2001-10-10 重庆医科大学 一种氮杂甾体化合物、制备及其用途
WO1997010217A1 (en) * 1995-09-15 1997-03-20 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
US6001844A (en) * 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
CZ289856B6 (cs) * 1996-02-05 2002-04-17 Sankyo Company Limited Farmaceutický prostředek na bázi inhibitoru 5alfa-reduktázy
HUP0001441A3 (en) * 1997-02-26 2001-03-28 Sankyo Company Ltd Chuo Ku Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
EP0998930B1 (en) 1997-07-29 2004-03-24 Sankyo Company Limited Azasteroid compound for treating alopecia, hirsutism and seborrhea
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
WO2004100874A2 (en) * 2003-05-07 2004-11-25 Merck & Co., Inc. Androgen receptor modulators and methods of use thereof
WO2005005606A2 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007522087A (ja) * 2003-06-30 2007-08-09 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体
EP1641535A4 (en) * 2003-06-30 2008-05-14 Merck & Co Inc 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20090123571A1 (en) * 2005-03-25 2009-05-14 Alan Meehan Method of treating men with testosterone supplement and 5alpha-reductase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4179453A (en) 1978-04-13 1979-12-18 Merck & Co., Inc. Process for preparing 17β-carboxy-5-androsten-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids

Also Published As

Publication number Publication date
JPH0819151B2 (ja) 1996-02-28
HUT59417A (en) 1992-05-28
EP0484094A2 (en) 1992-05-06
CN1209319A (zh) 1999-03-03
IE913747A1 (en) 1992-05-22
RU2070204C1 (ru) 1996-12-10
DE69120500D1 (de) 1996-08-01
ATE139783T1 (de) 1996-07-15
DK0484094T3 (da) 1996-10-28
JPH0532693A (ja) 1993-02-09
CZ279312B6 (cs) 1995-04-12
IE76452B1 (en) 1997-10-22
CN1053672C (zh) 2000-06-21
HU913396D0 (en) 1992-01-28
CA2054368A1 (en) 1992-04-30
HK1017274A1 (en) 1999-11-19
CA2054368C (en) 2001-10-02
PT99371A (pt) 1992-09-30
AU640279B2 (en) 1993-08-19
CN1072935C (zh) 2001-10-17
ES2091299T3 (es) 1996-11-01
US5302621A (en) 1994-04-12
HK1005456A1 (en) 1999-01-08
PT99371B (pt) 1999-04-30
HU218667B (hu) 2000-10-28
IL99889A0 (en) 1992-08-18
CS326991A3 (en) 1992-05-13
EP0484094B1 (en) 1996-06-26
HU211642A9 (en) 1995-12-28
GR3020483T3 (en) 1996-10-31
KR920008063A (ko) 1992-05-27
ZA918570B (en) 1992-08-26
KR0134570B1 (ko) 1998-04-14
EP0484094A3 (en) 1993-07-14
AU8682191A (en) 1992-04-30
DE69120500T2 (de) 1997-02-27
CN1062145A (zh) 1992-06-24

Similar Documents

Publication Publication Date Title
US5302621A (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
US5155107A (en) 17β-substituted-4-aza-5α-androstan-3-one derivatives and process for their preparation
US5693809A (en) Substituted 4-aza-5α-androstan-ones as 5α-reductase inhibitors
US5536727A (en) 17-Ethers and thioethers of 4-aza-steroids
AU668181B2 (en) Ester derivatives of 4-aza-steroids
US4845104A (en) Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US5620986A (en) 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
HUT74613A (en) 16-substituted-4-aza-androstane derivatives as 5-alpha-reductase isozyme 1 inhibitors and pharmaceutical compositions containing the same
EP0649431B1 (en) 17-amino substituted 4-azasteroid 5-alpha-reductase inhibitors
CZ67893A3 (en) Steroidal derivatives process of their preparation and pharmaceutical preparations in which they are comprised
JP3226919B2 (ja) 不飽和の17β―置換―3―カルボキシステロイド
CA2045867A1 (en) N-monosubstituted adamantyl/norbornanyl 17_beta-carbamides of 3-carboxy-androsts-3,5-dienes as testosterone 5 alpha-reductase inhibitors

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees